Nebivolol Sandoz (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic antagonist used in the management of cardiovascular conditions, primarily hypertension.

• Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications in adults.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which lowers cardiac output. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, thereby reducing peripheral vascular resistance and contributing to blood pressure control.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate headache reported.
• Dizziness: sensation of light‑headedness, especially on standing.
• Fatigue: general tiredness or lack of energy.
• Nausea: occasional stomach upset.
• Bradycardia: slower than normal heart rate.
• Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Hypotension: significant drop in blood pressure causing faintness.
• Bronchospasm: airway constriction, particularly in patients with asthma.
• Heart block: impaired electrical conduction in the heart.
• Allergic reactions: rash, itching, or swelling of face and throat.
• Hepatic injury: abnormal liver function tests or jaundice.

Before initiating Nebivolol therapy, several safety considerations should be observed.

• Blood pressure monitoring: check baseline and periodic readings.
• Cardiac assessment: evaluate heart rate and conduction abnormalities.
• Respiratory caution: avoid in uncontrolled asthma or severe COPD.
• Renal function: adjust use in patients with significant renal impairment.
• Discontinuation: do not stop abruptly; taper under medical supervision.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Other beta‑blockers: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): increased risk of AV block.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels.
• Clonidine withdrawal: may precipitate severe hypertension.
• Non‑selective beta‑agonists: antagonism reduces bronchodilation.

Moderate Interactions (Monitor Closely)

• Diuretics: enhanced antihypertensive effect, monitor electrolytes.
• NSAIDs: may blunt blood pressure reduction.
• Antihypertensives (ACE inhibitors, ARBs): additive blood pressure lowering.
• Insulin or oral hypoglycemics: possible masking of hypoglycemia symptoms.
• Antidepressants (sertraline, venlafaxine): monitor for dizziness or fatigue.